CD34 and acute myeloid leukemia: Notably, AML patients harboring NPM1 mutation, who in many cases often have <1% normal CD34+ cells11, expressed significantly lower TMIGD2 (Supplementary Table 2), suggesting that TMIGD2 is specifically expressed on the malignant CD34+ cells.